Cargando…
Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?
Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5–1% in the general population. Symptoms include positive (e.g., delusions, hallucinations), negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g., memory and attention problems)....
Autores principales: | Vingerhoets, Wilhelmina A. M., Bloemen, Oswald J. N., Bakker, Geor, van Amelsvoort, Therese A. M. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849802/ https://www.ncbi.nlm.nih.gov/pubmed/24363646 http://dx.doi.org/10.3389/fpsyt.2013.00157 |
Ejemplares similares
-
S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY
por: Vingerhoets, Claudia, et al.
Publicado: (2018) -
F144. MUSCARINIC M1 RECEPTOR SIGNALLING UNDERLYING COGNITION IN PSYCHOTIC DISORDERS
por: van Amelsvoort, Therese, et al.
Publicado: (2018) -
Relationship between muscarinic M(1) receptor binding and cognition in medication-free subjects with psychosis()
por: Bakker, Geor, et al.
Publicado: (2018) -
The muscarinic M(1) receptor modulates associative learning and memory in psychotic disorders
por: Bakker, Geor, et al.
Publicado: (2020) -
Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome
por: Bakker, Geor, et al.
Publicado: (2016)